Tocilizumab — Drug Intelligence | 124 EU Trials

Filter these 124 trials by condition, phase, country and more.

Open in Search →

124 Registered trials

51 Recruiting

54 Completed trials

60 Sponsors

26 Countries

Phase III

Phase II

Phase I/II

Phase I (FiH)

Phase III: 32 Phase II/III: 2 Phase II: 40 Phase I/II: 26 Phase III/IV: 1 Phase IV: 9 Phase I: 1 Phase I (FiH): 13

Oversight events:

5 serious breaches 30 temporary halts 4 urgent safety measures 22 unexpected events 9 corrective measures across 26 trials

View oversight register →

Indications tested

Follicular lymphoma 6 B-cell lymphoma refractory 4 Diffuse large B-cell lymphoma 3 Lupus nephritis 3 Diffuse large B-cell lymphoma recurrent 3 Juvenile idiopathic arthritis 3 Systemic lupus erythematosus 3 B-cell lymphoma recurrent 3 Primary mediastinal large B-cell lymphoma 2 Rheumatoid arthritis 2 Diffuse large B-cell lymphoma refractory 2 High-grade B-cell lymphoma 2

Sponsors using this IMP

F. Hoffmann-La Roche AG 15 Novartis Pharma AG 13 Assistance Publique Hopitaux De Paris 9 Genmab A/S 5 AstraZeneca AB 4 Celgene Corp. 4 Regeneron Pharmaceuticals Inc. 4 Amgen Inc. 3 Kite Pharma Inc. 3 Merck Sharp & Dohme LLC 3 Miltenyi Biomedicine GmbH 3 Aalborg University Hospital 2

All trials

124 total

A phase III, randomised, double-blind, multicentre study comparing the efficacy, safety, and immunogenicity of proposed tocilizumab biosimil… Not authorised

2022-501361-44-00 Phase III 7 countries Dr. Reddy's Laboratories Limited
Testing the safety and efficacy of combining biologic drugs in Rheumatoid and Psoriatic Arthritis Not authorised

2024-518011-19-00 Phase II 1 country Cardiff University
Comparison of treatment efficacy in the patients with Systemic sclerOsis: dapagliFlozin vs. Tocilizumab – a randomized head to head study Not authorised

2025-523714-92-00 Phase II 1 country Centrum Medyczne Ksztalcenia Podyplomowego
DALY II USA/MB-CART2019.1 for DLBCL Pending

2023-508508-39-01 Phase II 2 countries Miltenyi Biomedicine GmbH
TociCCAre - Clinical trial evaluating tocilizumab for the treatment of chondrocalcinosis Pending

2024-515956-19-00 Phase III 1 country Assistance Publique Hopitaux De Paris
A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active convent… Pending

2024-516723-14-00 Phase IV 4 countries Karolinska Institutet
Testing the safety and efficacy of combining biologic drugs in Rheumatoid and Psoriatic Arthritis Pending

2024-518011-19-01 Phase II 1 country Cardiff University
Tocilizumab Dose Optimization in Rheumatoid Arthritis Pending

2025-520513-30-00 Phase IV 1 country Reade revalidatie & reumatologie centrum te Amsterdam
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (SMART-JIA) Pending

2025-520923-25-00 Phase III 3 countries Duke Clinical Research Institute
A randomized placebo-controlled double-blind trial phase II two-arm study to investigate infarct growth over 72 hours assessed with diffusio… Pending

2025-521269-28-00 Phase II 1 country Oslo University Hospital HF
PALETTE - Trial for personalisation of sepsis treatment in children and adults Pending

2025-521371-31-00 Phase II 1 country Assistance Publique Hopitaux De Paris
Study comparing two dosing methods of tocilizumab in patients with rheumatoid arthritis in remission or with low disease activity Pending

2025-522319-41-00 Phase IV 1 country Centre Hospitalier Universitaire De Nice
A clinical trial to learn more about the effects of DJI136 in people with extensive-stage small cell lung cancer Pending

2025-523276-23-00 Phase I (FiH) 2 countries Novartis Pharma AG
A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with sta… Pending

2025-523869-22-00 Phase III 14 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH
Study of BMS-986353, CD19-CAR T Cells, versus SoC in Participants with Active SSc (Breakfree-SSc) Pending

2025-524337-11-00 Phase III 4 countries Celgene Corp.
The OASE study Pending

2026-525221-21-01 Phase IV 1 country Aalborg University Hospital
A clinical trial of MK-1045 in people with B-cell acute lymphoblastic leukemia Recruiting

2025-522267-15-00 Phase II/III 7 countries Merck Sharp & Dohme LLC
DAREON®-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide t… Recruiting

2025-520565-51-00 Phase III 20 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH
A clinical trial of MK-1045 and rituximab in people with follicular lymphoma (MK-1045-007) Recruiting

2025-522777-10-00 Phase II/III 2 countries Merck Sharp & Dohme LLC
A clinical study of MK-1045 in people with non-Hodgkin lymphoma (MK-1045-008) Recruiting

2025-523005-15-00 Phase I/II 5 countries Merck Sharp & Dohme LLC
A study to test the safety and disease progression following YTB323 (rapcabtagene autoleucel) administration in participant with progressive… Recruiting

2024-514006-31-00 Phase I/II 4 countries Novartis Pharma AG
An open-label study to assess the safety, efficacy, and cellular kinetics of YTB323 (rapcabtagene autoleucel) in Relapsingin Relapsing Multi… Recruiting

2024-512714-18-00 Phase I/II 4 countries Novartis Pharma AG
A study to determine how safe MB-CART2019.1 is and how well it works in children and adolescents with B cell neoplasms Recruiting

2023-506348-17-00 Phase II 4 countries Miltenyi Biomedicine GmbH
Toward personalized medicine to guide drug withdrawal in children with juvenile idiopathic arthritis in clinical remission: a randomized cli… Recruiting

2024-514732-24-00 Phase IV 7 countries IRCCS Istituto Giannina Gaslini

Showing 1–24 of 124 trials

← All drugs A–Z